Eli Lilly and Company (LLY)vsSolventum Corp. (SOLV)
LLY
Eli Lilly and Company
$1,131.42
-0.26%
HEALTHCARE · Cap: $948.95B
SOLV
Solventum Corp.
$81.01
-1.71%
HEALTHCARE · Cap: $14.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 774% more annual revenue ($72.25B vs $8.26B). LLY leads profitability with a 35.0% profit margin vs 17.3%. SOLV appears more attractively valued with a PEG of 1.22. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
SOLV
Buy60
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Attractively priced relative to earnings
Every $100 of equity generates 29 in profit
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
Distress zone — elevated risk
Elevated debt levels
Revenue declined 3.0%
Earnings declined 91.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : SOLV
The strongest argument for SOLV centers on P/E Ratio, Return on Equity, Price/Book. Profitability is solid with margins at 17.3% and operating margin at 5.6%. PEG of 1.22 suggests the stock is reasonably priced for its growth.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Bear Case : SOLV
The primary concerns for SOLV are Altman Z-Score, Debt/Equity, Revenue Growth.
Key Dynamics to Monitor
LLY profiles as a growth stock while SOLV is a declining play — different risk/reward profiles.
SOLV carries more volatility with a beta of 0.75 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 60/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Solventum Corp.
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. The company is headquartered in Saint Paul, Minnesota.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?